HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with HER2-positive stomach or gastroesophageal junction cancer that has spread or can't be removed with surgery.
- You have not received any prior treatment for this cancer (except possibly neoadjuvant or adjuvant therapy if it's been more than 6 months since you completed it).
- You have not had any prior HER2-targeted therapy (like trastuzumab or other similar drugs).
- You are able to perform daily activities without significant help (ECOG score 0 or 1).
- You have no active bleeding in your stomach or intestines, and no cancer spread to the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
This trial tests a combination of immunotherapy (serplulimab), a targeted HER2 therapy (trastuzumab), and chemotherapy (SOX) after stomach cancer surgery. The goal is to see if this combination reduces the chance of cancer returning in people with HER2-positive stomach cancer.
Hear when a new Gastroesophageal-junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.